Key Factors Aligning To Short Pharmaceuticals [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
Key Factors Aligning To Short Pharmaceuticals Summary Presidential Executive Orders and Congressional Bills that could harm the industry are this expected summer. In 2019 and 2023 large patents will expire that are expected to cost the industry $250 Billion in sales by 2024. Technical trends and key price levels favor short selling pharmaceutical firms. Today it seems there are very few areas for which Democrats and Republicans agree. On most issues Americans have come to expect little change by congress due to extreme levels of partisanship. One of the few areas where bipartisan consensus is growing is that Pharmaceutical firms are a primary culprit in growing exorbitant healthcare costs. Currently, roughly 20% of the United States’ GDP goes to Healthcare which is about twice as much as other developed nations. About a quarter Regulatory risk for companies like those within SPDR’s Pharmaceutical ETF XPH Declining Revenue Growth Potential The industry as a whole has seen very high top
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Autoimmune Hepatitis Diagnosis and Treatment Market Size to Reach USD 19.15 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six [Yahoo! Finance]Yahoo! Finance
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixBusiness Wire
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 3/28/24 - Form ARS
- 3/28/24 - Form DEF
- 3/28/24 - Form DEFA14A
- GILD's page on the SEC website